NCT05276700|Unknown
Loading search results
Sponsor study identifier
observational
170
0 countries
N/A
Study Start
July 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
find the role of alpha one microglobulin (as an early renal tubular biomarker) to identify and evaluate the prevalence of early renal manifestations among patients with chronic HCV and compared these patients with HCV-negative healthy individuals
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 3, 2022
Actual (reported)March 11, 2022
Actual (reported)July 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
to identify and evaluate the prevalence of early renal manifestations among patients with chronic HCV by using alpha one microglobulin (as an early renal tubular biomarker).
to identify and evaluate the prevalence of early renal manifestations among patients with chronic HCV by using alpha one microglobulin (as an early renal tubular biomarker).
marsh 2022 - February 2024
170 participants in 1:1 design (79 HCV positive patient were diagnosed as HCV positive by HCV+Abs and +ve real time PCR for HCV-RNA and 79 age and sex matched HCV negative as control, and fulfill the following inclusions criteria
Cacoub P, Comarmond C. Considering hepatitis C virus infection as a systemic disease. Semin Dial. 2019 Mar;32(2):99-107. doi: 10.1111/sdi.12758. Epub 2018 Dec 13.
Aguirre Valadez J, Garcia Juarez I, Rincon Pedrero R, Torre A. Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review. Ther Clin Risk Manag. 2015 Feb 27;11:329-38. doi: 10.2147/TCRM.S74282. eCollection 2015.
Enas Alkareemy
Assiut University
First Submitted
March 3, 2022
First Posted
March 11, 2022
Study Start
July 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 2024
Innovate, Involve, Inspire
Contact the study team to confirm eligibility.
Kaartinen K, Vuoti S, Honkanen E, Loyttyniemi E, Singh R, Farkkila M. Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C. PLoS One. 2021 May 7;16(5):e0251392. doi: 10.1371/journal.pone.0251392. eCollection 2021.
Itoh Y, Kawai T. Human alpha 1-microglobulin: its measurement and clinical significance. J Clin Lab Anal. 1990;4(5):376-84. doi: 10.1002/jcla.1860040511.
Weber MH, Verwiebe R. Alpha 1-microglobulin (protein HC): features of a promising indicator of proximal tubular dysfunction. Eur J Clin Chem Clin Biochem. 1992 Oct;30(10):683-91.
Heise D, Rentsch K, Braeuer A, Friedrich M, Quintel M. Comparison of urinary neutrophil glucosaminidase-associated lipocalin, cystatin C, and alpha1-microglobulin for early detection of acute renal injury after cardiac surgery. Eur J Cardiothorac Surg. 2011 Jan;39(1):38-43. doi: 10.1016/j.ejcts.2010.05.044. Epub 2010 Jul 21.
Amer H, Lieske JC, Rule AD, Kremers WK, Larson TS, Franco Palacios CR, Stegall MD, Cosio FG. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant. 2013 Mar;13(3):676-84. doi: 10.1111/ajt.12044. Epub 2013 Feb 15.
Bullen AL, Katz R, Lee AK, Anderson CAM, Cheung AK, Garimella PS, Jotwani V, Haley WE, Ishani A, Lash JP, Neyra JA, Punzi H, Rastogi A, Riessen E, Malhotra R, Parikh CR, Rocco MV, Wall BM, Bhatt UY, Shlipak MG, Ix JH, Estrella MM. The SPRINT trial suggests that markers of tubule cell function in the urine associate with risk of subsequent acute kidney injury while injury markers elevate after the injury. Kidney Int. 2019 Aug;96(2):470-479. doi: 10.1016/j.kint.2019.03.024. Epub 2019 May 7.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 4, 2022
Record last verified: 2022-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: